2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVOX 2倍做多NVO ETF-Defiance

未开盘 03-18 16:00:00 EDT

10.14

-0.51

-4.79%

盘后10.04

-0.10-0.99%

19:58 EDT

最高10.25	最低9.87	成交量108.61万
今开10.10	昨收10.65	日振幅3.52%
总市值4,399万	流通市值4,399万	总股本433.81万
成交额1,093万	换手率25.04%	流通股本433.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":10.14,"timestamp":1773864000000,"preClose":10.65,"halted":0,"volume":1086080,"hourTrading":{"tag":"盘后","latestPrice":10.04,"preClose":10.14,"latestTime":"19:58 EDT","volume":16132,"amount":162553.6867,"timestamp":1773878318197,"change":-0.1,"changeRate":-0.009862,"amplitude":0.016765},"delay":0,"changeRate":-0.04788732394366195,"floatShares":4338101,"shares":4338101,"eps":0,"marketStatus":"未开盘","change":-0.51,"latestTime":"03-18 16:00:00 EDT","open":10.1,"high":10.245,"low":9.87,"amount":10929198.06016,"amplitude":0.035211,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1773907200000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":10.65,"sharesOutstanding":4128101,"nav":10.66,"aum":45497956.66,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":10.099,"preClose":10.65,"latestTime":"09:29 EDT","volume":71580,"amount":732130.76226,"timestamp":1773840571272,"change":-0.551,"changeRate":-0.051737,"amplitude":0.034836},"postHourTrading":{"tag":"盘后","latestPrice":10.04,"preClose":10.14,"latestTime":"19:58 EDT","volume":16132,"amount":162553.6867,"timestamp":1773878318197,"change":-0.1,"changeRate":-0.009862,"amplitude":0.016765},"volumeRatio":1.011948,"impliedVol":0.7275,"impliedVolPercentile":0.348},"requestUrl":"/m/hq/s/NVOX","defaultTab":"news","newsList":[{"id":"2620476890","title":"Structure肥胖药物研究结果直追诺和诺德与礼来","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476890","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620476890?lang=zh_cn&edition=full","pubTime":"2026-03-17 23:08","pubTimestamp":1773760090,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0114720955.EUR","LU0109394709.USD","LU2237443465.HKD","LU0689472784.USD","GB00BDT5M118.USD","LU2168564149.EUR","BK4532","LU2023251221.USD","LU0198837287.USD","NVOH","LU0097036916.USD","LU2112291526.USD","LU2023250330.USD","LU2491050071.SGD","LU1548497426.USD","SG9999018865.SGD","LU1061106388.HKD","IE0009355771.USD","LU0094547139.USD","LU2750360997.AUD","LU0006306889.USD","LU2023250504.SGD","LU2108987350.USD","SGXZ57979304.SGD","LU2552382058.USD","IE00BJT1NW94.SGD","SG9999001176.SGD","LU0203201768.USD","LU0320765992.SGD","IE0004445239.USD","LU0096364046.USD","LU1093756168.USD","LU0158827781.USD","LU0122379950.USD","LU2361045086.USD","LU0471298777.SGD","LU2237443978.SGD","LU0225283273.USD","LU2089284900.SGD","IE00BFSS7M15.SGD","LU2471134879.HKD","SGXZ51526630.SGD","LU0943347566.SGD","LU2168564222.USD","BK4599","LU0234572021.USD","LU0385154629.USD","SG9999015945.SGD","LU0889565916.HKD","IE00B7KXQ091.USD","IE00B775H168.HKD","SG9999001176.USD","LU0158827948.USD","LU1064131342.USD","IE00BN29S564.USD","LU0210536198.USD","LU2491050154.USD","SG9999015986.USD","IE00B4R5TH58.HKD","LU0079474960.USD","LU1917777945.USD","IE00BKPKM429.USD","LU0823416689.USD","LU2896262040.SGD","LU2237443549.SGD","LU0882574139.USD","LU0708995401.HKD","LU1868836591.USD","LU1145028129.USD","LU0238689110.USD","LU2602419157.SGD","SG9999014898.SGD","LU0820562030.AUD","BK4516","LU1868837300.USD","LU0353189763.USD","LU2471134952.CNY","LU1366192091.USD","NVOX","LU0203202063.USD","LU1629891620.HKD","LU1814569148.SGD","LU0289739699.SGD","LU0820561818.USD","IE00B1XK9C88.USD","LU2746668461.USD","SG9999014906.USD","IE00BZ1G4Q59.USD","SG9999014914.USD","LU1623119135.USD","LU1720051108.HKD","LU2237443622.USD","LU0640476718.USD","LLII","IE00BWXC8680.SGD","LU1023059063.AUD","IE0004445015.USD","SGXZ99366536.SGD","LU0823434583.USD","ELIS","LU0354030438.USD","LU2213496289.HKD","LU2264538146.SGD","LU2168564495.EUR","LU2271345857.HKD","LU0353189680.USD","LU1720051017.SGD","LU2471134796.USD","LU0106261372.USD","LU2168564065.EUR","LU0466842654.USD","BK4581","GPCR","LU2237443895.HKD","LU2087625088.SGD","LU2361044949.HKD","LU0787776722.HKD","LU1868836757.USD","LU2461242641.AUD","LLYX","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU2746668974.SGD","LU0683600562.USD","SGXZ31699556.SGD","LU1093756325.SGD","LU0820561909.HKD","SG9999015978.USD","LU0320765059.SGD","LU1127390331.HKD","LU1712237335.SGD","LU1267930730.SGD","BK4588","IE00B4JS1V06.HKD","IE00BFTCPJ56.SGD","LU1988902786.USD","LU2237443382.USD","LU2756315664.SGD","LU1804176565.USD","LU2471134523.USD","LU2552382215.SGD","LLYZ","BK4007","LU2168563687.JPY","LU0471298694.HKD","LU2552382132.HKD","IE00B1BXHZ80.USD","LU1983299246.USD","LU2236285917.USD","LU1989771016.USD","LU0672654240.SGD","LU2111349929.HKD","LU2750360641.GBP","IE00BK4W5M84.HKD","SGXZ81514606.USD","BK4534","LU1057294990.SGD","LU0882574055.USD","LU0154236417.USD","LU1232071149.USD","LU2089984988.USD","SG9999013999.USD","LU0316494557.USD","LU0417517546.SGD","LU2237438978.USD","LU2357305700.SGD","LU0266013472.USD","LU0823434740.USD","IE00BJJMRY28.SGD","LU1323610961.USD","LU1868837136.USD","IE0001KFT4U8.USD","LU2456880835.USD","SG9999014880.SGD","LU2491049909.HKD","SG9999015952.SGD","LU2360106947.USD","IE00BJLML261.HKD","LU0456855351.SGD","IE00BKVL7J92.USD","LU2756315318.SGD","LU2265009873.SGD","LU0354030511.USD","LU1868836914.USD","LU2028103732.USD","LU0256863811.USD","LU0964807845.USD","ELIL","IE00B2B36J28.USD","IE00BJJMRX11.SGD","LU1035775433.USD","LU2324357040.USD","LU2063271972.USD","IE00BFSS8Q28.SGD","LU1069344957.HKD","SG9999017495.SGD","LU1280957306.USD","LU2106854487.HKD","LU1551013342.USD","LU2417539215.USD","LU0432979614.USD","LU1974910355.USD","LU2089283258.USD","IE0002141913.USD","IE00BK4W5L77.USD","LU1551013425.SGD","BK4533","IE0005OL40V9.USD","SG9999018857.SGD","IE00BKDWB100.SGD","BK4585","LU2361044865.SGD","LU2211815571.USD","LU0061475181.USD","LU0256863902.USD","LU2468319806.SGD","LU0058720904.USD","LU0323591593.USD","LU0786609619.USD","LU0109391861.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2618138250","title":"Hims & Hers Health(HIMS)盘前涨8% 日前与诺和诺德建立新的合作伙伴关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138250","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618138250?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:08","pubTimestamp":1773310089,"startTime":"0","endTime":"0","summary":"金吾财讯 | Hims & Hers Health 盘前涨8%，截至发稿，报27.950美元。消息面上，日前，Hims & Hers Health与诺和诺德建立新的合作伙伴关系，专注于提供品牌药物。两家公司于周一表示，诺和诺德已同意在Hims & Hers Health平台上销售其王牌药物Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德将撤回上个月针对Hims & Hers Health提起的诉讼。作为回报，Hims & Hers Health表示将不再为其仿制版诺和诺德药物投放广告。但如果医生认为患者有必要使用，该公司仍将销售Wegovy和Ozempic的复配版本。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297963","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4599","LU1093756168.USD","HIYY","NVOH","BK4532","IE00BKVL7J92.USD","HIMS","IE00BZ1G4Q59.USD","NVOX","BK4588","LU0154236417.USD","HIMY","BK4007","HMYY","HIMZ","BK4585","LU1093756325.SGD"],"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","IE00BKVL7J92.USD","REGN","LU0757428866.USD","NVOH","NVO","BK4121","BK4599","LU1815336091.USD","BK4585","INCY","LU0128526141.USD","BK4530","LU0029874061.USD","NVOX","LU1093756325.SGD","BK4007","BK4588","IE00BZ1G4Q59.USD","AZN","LU0390134368.USD","IE00BFMHRM44.USD","BK4532","LU0154236417.USD"],"gpt_icon":0},{"id":"2618963769","title":"诺和诺德旗下“问题”工厂，又一家药企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618963769?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOH","NVOX","LU1093756168.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU0154236417.USD","NVO","BK4532","BK4588","BK4585","BK4599","BK4007","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2618895342","title":"Hims & Hers与诺和诺德达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2618895342","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618895342?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:03","pubTimestamp":1773147780,"startTime":"0","endTime":"0","summary":"Hims & Hers与诺和诺德结束诉讼，Hims将停止推广复方胰高血糖素样肽-1药物，并通过其平台提供威戈维和奥泽匹克；Hims股价大涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6182604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","HIMS","BK4585","LU1093756325.SGD","LU1093756168.USD","NVOX","LU0154236417.USD","BK4599","BK4532","NVOH","NVO"],"gpt_icon":0},{"id":"2618933958","title":"跨国药企2025年成绩单：“药王”易主，创新资产交易创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618933958?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:04","pubTimestamp":1773133472,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增速，实现651.79亿美元的全年营收，成为增速最快的头部药企。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667509930.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667509930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BLSP4452.SGD","MRK","BK4550","BK4588","LU1989772840.SGD","LU2360032135.SGD","BK4534","LU0320765489.SGD","LU1066051811.HKD","LU0868494617.USD","LU0648001328.SGD","NVOX","LU0203347892.USD","LU2361044865.SGD","LU2125154778.USD","NVOH","LU0289739699.SGD","CDE","LU1057294990.SGD","SG9999014575.USD","LU1934455863.HKD","IE00BKVL7J92.USD","BK4516","IE00BN8TJ469.HKD","01477","LU0130517989.USD","SG9999015358.SGD","IE00BJJMRZ35.SGD","LU2324357040.USD","LU1023059063.AUD","NVO","LU1223082519.USD","SG9999014542.SGD","LU0098860793.USD","GSK.UK","LU2361045086.USD","LU1093756325.SGD","SGXZ57979304.SGD","BK4559","SG9999001176.USD","LU1983299246.USD","GSK","LU0477156953.USD","LU0266013472.USD","GSKH","LU1291159041.SGD","LU1571399168.USD","LU1066051225.USD","BK4585","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2618147987","title":"花旗上调Hims & Hers Health(HIMS.US)评级至“中性” 看好诺和诺德协议下的合规溢价","url":"https://stock-news.laohu8.com/highlight/detail?id=2618147987","media":"智通财经","labels":["executive","rating"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618147987?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:07","pubTimestamp":1773130046,"startTime":"0","endTime":"0","summary":"花旗银行在最新的研究报告中对这一合作给予了高度评价，并将其视为 Hims & Hers 发展史上的重要转折点。花旗分析师指出，通过引入官方正版药物，Hims & Hers 成功摆脱了长期困扰其业务模式的合规性阴影与法律风险。这一利好消息在二级市场引发了剧烈反弹，Hims & Hers 的股价在消息公布后的交易时段内一度飙升超过 35%，周一收涨40.79%，报22.16美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,rating","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4566","NVOH","NVOX","HIMZ","LU1791807156.HKD","LU1506573853.SGD","LU0162691827.USD","LU1201861249.SGD","LU0052756011.USD","BK4559","LU0098860793.USD","LU1668664300.SGD","BK4532","LU0130517989.USD","IE00BKVL7J92.USD","LU2462157665.USD","BK4007","LU0130102774.USD","IE00BSNM7G36.USD","LU1366192091.USD","HIYY","LU2417539215.USD","LU2125154935.USD","BK4585","LU0154236417.USD","LU1244550577.SGD","HIMS","BK4196","LU0320765646.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1162221912.USD","LU0314106906.USD","BK4207","LU2456880835.USD","LU0170899867.USD","BK4504","LU0106831901.USD","LU2125154778.USD","LU2360032135.SGD","LU0648001328.SGD","LU0072461881.USD","LU0128525689.USD","LU1093756325.SGD","LU0477156953.USD","BK4599","LU0980610538.SGD","HIMY","LU2236285917.USD","LU1244550494.USD","LU0310800965.SGD","HMYY","LU1267930227.SGD","LU1244550221.USD","BK4588","BK4534"],"gpt_icon":1},{"id":"2618672446","title":"3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618672446?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。　　摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。　　此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。　　该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","IE00BZ1G4Q59.USD","BK4196","NVOX","HIYY","NVOH","BK4599","BK4007","LU1093756168.USD","IE00BKVL7J92.USD","LU0154236417.USD","HIMS","NVO","BK4532","HMYY","LU1093756325.SGD","HIMY","HIMZ","BK4585"],"gpt_icon":1},{"id":"2618781516","title":"诺和诺德盘中异动 股价大涨3.00%报39.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618781516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618781516?lang=zh_cn&edition=full","pubTime":"2026-03-10 00:15","pubTimestamp":1773072908,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日00时15分，诺和诺德股票出现异动，股价急速拉升3.00%。截至发稿，该股报39.74美元/股，成交量1310.03万股，换手率0.29%，振幅3.21%。诺和诺德股票所在的制药行业中，整体跌幅为0.48%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BKVL7J92.USD","NVO","LU1093756168.USD","BK4599","BK4585","BK4532","LU1093756325.SGD","BK4588","NVOH","IE00BZ1G4Q59.USD","NVOX","LU0154236417.USD"],"gpt_icon":1},{"id":"2618621200","title":"分析师：Hims & Hers本身不会通过诺和诺德的GLP-1s药物盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621200","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618621200?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:43","pubTimestamp":1773063796,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","HIMS","LU0154236417.USD","BK4590","IE00BKVL7J92.USD","BK4144","IE00BZ1G4Q59.USD","BK4599","BK4585","BK4532","BK4007","NVOX","LU1093756168.USD","NVOH","LU1093756325.SGD"],"gpt_icon":0},{"id":"1162171962","title":"Hims与诺和诺德合作或引发短期逆风——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1162171962","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162171962?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:53","pubTimestamp":1773060828,"startTime":"0","endTime":"0","summary":"早盘8点49分——Hims & Hers Health Inc.股价因诺和诺德终止对其诉讼并达成合作的消息而大幅飙升。根据协议，Hims平台将引入诺和诺德的GLP-1类药物。Truist分析师指出，尽管此举消除了Hims面临的重要法律风险，但合作可能对其短期业务造成冲击。\n作为协议的一部分，Hims将停止销售复合GLP-1药物，而这类药物曾贡献其大部分营收。不过，品牌GLP-1药物的收入持续性显著更高，尤其考虑到Hims的复合药物此前一直面临法律威胁。分析师认为，这一转变可能促使投资者愿意给予Hims更高估值倍数。受此影响，Hims股价在盘前交易中猛涨51%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMS","LU1093756325.SGD","LU0154236417.USD","BK4196","HIMY","LU1093756168.USD","HIYY","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOH","BK4532","BK4599","HIMZ","BK4007","HMYY","NVOX","BK4585","BK4588"],"gpt_icon":0},{"id":"2618356626","title":"诺和诺德确认将在HIMS & HERS平台上销售WEGOVY、OZEMPIC产品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618356626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618356626?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059515,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BK4532","BK4196","BK4599","NVOH","HIMS","BK4585","NVO","IE00BZ1G4Q59.USD","LU1093756325.SGD","HIYY","LU1093756168.USD","HIMZ","BK4588","HIMY","IE00BKVL7J92.USD","LU0154236417.USD","NVOX","HMYY"],"gpt_icon":0},{"id":"2617656092","title":"Hims & Hers Health美股盘后涨近37%，报道称诺和诺德计划在Hims的平台上销售其减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617656092","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617656092?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:48","pubTimestamp":1772844525,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4550","TWM","LU0154236417.USD","NVOH","SRTY","BK4599","IE00BKVL7J92.USD","BK4007","UWM","LU1093756325.SGD","BK4535","LU1093756168.USD","HIMS","IWO","IE00BZ1G4Q59.USD","TNA","BK4532","RWM","BK4585","BK4588","BK4581","NVOX","TZA","IWN","MNQmain","NVO","BK4534"],"gpt_icon":0},{"id":"2617262656","title":"诺和诺德和HIMS将共同销售减肥药，结束双方的争端。","url":"https://stock-news.laohu8.com/highlight/detail?id=2617262656","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617262656?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:34","pubTimestamp":1772843680,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVO","HIYY","NVOX","NVOH","BK4532","BK4599","HIMY","BK4007","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4196","HIMZ","BK4585","LU0154236417.USD","LU1093756168.USD","HMYY","LU1093756325.SGD","HIMS"],"gpt_icon":0},{"id":"2617463761","title":"速递｜一针一周的组合拳：IcoSema在华获批，诺和诺德把胰岛素和GLP-1装进同一支笔","url":"https://stock-news.laohu8.com/highlight/detail?id=2617463761","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617463761?lang=zh_cn&edition=full","pubTime":"2026-03-06 23:24","pubTimestamp":1772810690,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队3月6日，国家药监局官网信息显示，诺和诺德的依柯胰岛素司美格鲁肽注射液 IcoSema 在中国获批上市，用于2型糖尿病治疗。IcoSema由两种活性成分组成。两者在中国此前都已分别获批上市，如今用复方形式打包，意味着诺和诺德把周制剂胰岛素的便利性与GLP-1的代谢收益，直接做成一条更省事的治疗路径。IcoSema的商业逻辑就在这里：把加用胰岛素和加用GLP-1这两步，尽量合并成一步，减少决策成本和执行成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603070219219543bc6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603070219219543bc6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","BK4590","NVO","BK4599","LU1093756325.SGD","LU1093756168.USD","NVOH","BK4585","IE00BKVL7J92.USD","NVOX","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4532","BK4144"],"gpt_icon":1},{"id":"2617831166","title":"今日，诺和诺德 GLP-1 联合制剂国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2617831166","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617831166?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:50","pubTimestamp":1772783431,"startTime":"0","endTime":"0","summary":"3 月 6 日，NMPA 官网显示，诺和诺德“依柯胰岛素+司美格鲁肽-IcoSema”在国内获批上市。根据公开信息和临床试验进展，Insight 数据库推断本次获批的适应症为用于在饮食和运动的基础上，接受基础胰岛素或 GLP-1 受体激动剂治疗控制不佳的成人 2 型糖尿病患者的治疗。2025 年 11 月，该药获欧洲药品管理局批准上市，用于治疗成人 2 型糖尿病，成为全球首个基础胰岛素 GLP-1RA 周制剂。胰岛素剂量方面，相较于依柯胰岛素组，IcoSema 组胰岛素剂量显著减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161755a6aa2ba6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161755a6aa2ba6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOH","BK4588","IE00BKVL7J92.USD","LU0154236417.USD","BK4144","NVOX","NVO","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","BK4007","BK4599","BK4585","BK4590"],"gpt_icon":1},{"id":"2617577411","title":"诺和诺德“司美格鲁肽”治疗MASH拟纳入优先审评，即将惠及国内广大MASH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577411","media":"药研途","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617577411?lang=zh_cn&edition=full","pubTime":"2026-03-06 07:28","pubTimestamp":1772753310,"startTime":"0","endTime":"0","summary":"2026年3 月 3 日，CDE 官网显示，诺和诺德“司美格鲁肽注射液”新适应症在国内申报上市，并拟纳入优先审评，适应症为：用于治疗代谢相关脂肪性肝炎伴中重度肝纤维化的非肝硬化成人患者。全球约有2.5亿MASH患者，其中超过三分之一的超重或肥胖人群同时患有MASH，疾病负担日益加重。司美格鲁肽治疗MASH的作用机制司美格鲁肽通过多重直接与间接途径改善MASH病理进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4599","BK4588","BK4532","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4007","NVO","LU1093756325.SGD","NVOX","IE00BZ1G4Q59.USD","NVOH"],"gpt_icon":1},{"id":"2617254074","title":"礼来瞄准雇主GLP-1覆盖 以与诺和诺德竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2617254074","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617254074?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:39","pubTimestamp":1772717940,"startTime":"0","endTime":"0","summary":"礼来公司推出“Employer Connect”，为新型多剂量Zepbound提供每月449美元的净价格，并与Teladoc Health和GoodRx等合作伙伴整合，以扩大肥胖药物的可及性；诺和诺德仍是主要竞争对手。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-05/doc-inhpycce3059268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0109394709.USD","LU1061106388.HKD","BK4590","LU0466842654.USD","LU0820561909.HKD","LU1712237335.SGD","LU1323610961.USD","BK4534","LU2750360997.AUD","IE0004445015.USD","BK4581","LU0640476718.USD","SGXZ57979304.SGD","IE00BFSS7M15.SGD","LLYZ","GB00BDT5M118.USD","LU2063271972.USD","LU0471298694.HKD","SG9999001176.USD","BK4007","LU1804176565.USD","SG9999015978.USD","LU0097036916.USD","LU2491050154.USD","LU0820562030.AUD","SGXZ81514606.USD","LU0158827948.USD","IE0004445239.USD","LU0323591593.USD","SG9999015986.USD","LU2265009873.SGD","LU0689472784.USD","IE0005OL40V9.USD","LU1868836591.USD","LU1868836757.USD","LU0094547139.USD","LU2213496289.HKD","LU2237438978.USD","LU2089283258.USD","LU0320765059.SGD","LU2552382058.USD","LU1720051108.HKD","LU2361044949.HKD","LU1127390331.HKD","LU2602419157.SGD","LU2271345857.HKD","SG9999014914.USD","LU0353189763.USD","LU2552382132.HKD","LU0385154629.USD","LU0203202063.USD","LU1983299246.USD","LU2417539215.USD","LU2237443549.SGD","IE00B1BXHZ80.USD","LU1989771016.USD","LU1069344957.HKD","LU0882574055.USD","LU0432979614.USD","IE00BFSS8Q28.SGD","LU1291159041.SGD","LU2468319806.SGD","IE00BK4W5M84.HKD","SG9999018857.SGD","SG9999017495.SGD","LU1064131342.USD","LU2168563687.JPY","LU0943347566.SGD","IE00BN29S564.USD","LU0786609619.USD","LU2456880835.USD","LU0823434583.USD","LU2750360641.GBP","BK4533","LU0417517546.SGD","LU2089284900.SGD","NVOH","LU1093756325.SGD","LU0079474960.USD","LU0353189680.USD","LU0471298777.SGD","LU0354030438.USD","LU1232071149.USD","LU0061475181.USD","IE00B4R5TH58.HKD","LU1551013425.SGD","LU2552382215.SGD","LU2360106947.USD","SG9999018865.SGD","ELIS","LU0820561818.USD","LU0316494557.USD","LU2237443622.USD","IE0001KFT4U8.USD","LU2746668974.SGD","BK4585","LU2756315318.SGD","LU0106261372.USD","LU1280957306.USD","LU0354030511.USD","LLY","IE00BJLML261.HKD","LU0096364046.USD","LLYX","LU1720051017.SGD","LU2264538146.SGD","ELIL","LU0210536198.USD","SG9999014898.SGD","LU1974910355.USD","LU2471134523.USD","LU2491049909.HKD","LU2357305700.SGD","LU0238689110.USD","LU0256863902.USD","LU1551013342.USD","LU0672654240.SGD","LU2237443382.USD","LU1366192091.USD","SGXZ31699556.SGD","BK4516","LU2471134879.HKD","LU2023250504.SGD","IE00BK4W5L77.USD","IE00BFTCPJ56.SGD","LU2168564222.USD","LU2237443465.HKD","LU0154236417.USD","IE00BJJMRZ35.SGD","LU2087625088.SGD","LU2236285917.USD","IE0009355771.USD","SG9999015952.SGD","LU2237443895.HKD","LU2106854487.HKD","LU1145028129.USD","LU2028103732.USD","LU1868837300.USD","LU2023250330.USD","LU0122379950.USD","LU2471134796.USD","LU2324357040.USD","LU0964807845.USD","IE00BJJMRY28.SGD","LU0456855351.SGD","NVOX","LU2361044865.SGD","SG9999001176.SGD","LU1057294990.SGD","LU2211815571.USD","IE00BKDWB100.SGD","BK4144","LU0198837287.USD","IE00BKPKM429.USD","LU0266013472.USD","LU1868836914.USD","LU2108987350.USD","LU2237443978.SGD","LU0058720904.USD","IE00B775H168.HKD","LU0256863811.USD","LU1035775433.USD","LU1548497426.USD","LU1917777945.USD","LU2023251221.USD","LU1023059063.AUD","LU2168564495.EUR","LU2111349929.HKD","LU0158827781.USD","LU0320765992.SGD","LU0889565916.HKD","IE00BJJMRX11.SGD","LU0006306889.USD","LU1623119135.USD","LU2461242641.AUD","LU2491050071.SGD","LU0683600562.USD","IE00BZ1G4Q59.USD","LU2462157665.USD","LU1093756168.USD","IE0002141913.USD","BK4532","SGXZ99366536.SGD","LU1868837136.USD","IE00BJT1NW94.SGD","LU2471134952.CNY","LU1629891620.HKD","LU1814569148.SGD","BK4588","LU0708995401.HKD","LU2168564065.EUR","LU0787776722.HKD","SG9999013999.USD","LU0203201768.USD","IE00B2B36J28.USD","LU0289739699.SGD","BK4599","LU2361045086.USD","LU2746668461.USD","LU2089984988.USD","LU0882574139.USD","IE00BKVL7J92.USD","LU1267930730.SGD","SG9999015945.SGD","NVO","IE00B7KXQ091.USD","IE00B4JS1V06.HKD","SG9999014906.USD","IE00B1XK9C88.USD","LU0114720955.EUR","LU2112291526.USD","LU2756315664.SGD","SG9999014880.SGD","LU0823416689.USD","LU2168564149.EUR","SGXZ51526630.SGD","LU0109391861.USD","LLII","LU0234572021.USD","IE00BWXC8680.SGD","LU2896262040.SGD","LU1988902786.USD","LU0823434740.USD","LU0225283273.USD"],"gpt_icon":0},{"id":"2617959547","title":"诺和诺德、武田、默克等齐换帅，中国市场进入战略新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2617959547","media":"动脉网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617959547?lang=zh_cn&edition=full","pubTime":"2026-03-05 09:53","pubTimestamp":1772675580,"startTime":"0","endTime":"0","summary":"2026年以来，诺和诺德、武田、默克等多家跨国药企相继完成中国区“换帅”。费森尤斯卡比中国宣布张巍3月2日加入，4月3日起任总裁兼董事长，她拥有超二十年医药行业经验；罗杰仁2月1日起任默克中国总裁，1月1日起兼任默克生命科学中国负责人，在医药健康和生命科学领域经验丰富；穆安德2月1日起任默克中国医药健康业务董事总经理，他是内部提拔晋升而来；诺和诺德中国宣布周霞萍3月31日离任，蔡琰同日接任大中国区总裁，周霞萍助力公司10款新药获批上市，蔡琰是资深管理者；1月底武田制药任命刘燕为武田中国总裁，负责整体战略和业务发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014567.USD","LU2361045086.USD","LU0868494617.USD","BK4588","KWEB","LU1162221912.USD","LU1116320901.HKD","LU0648001328.SGD","LU1699723380.USD","LU1917777945.USD","LU1116320737.USD","LU1571399168.USD","LU0265550359.USD","LU0477156953.USD","LU1066053197.SGD","LU0211331839.USD","LU0238689110.USD","LU1941712348.USD","LU0965508806.USD","LU0070302665.USD","LU0203347892.USD","SGXZ57979304.SGD","LU0130517989.USD","LU2468319806.SGD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0985320562.USD","SG9999001176.USD","LU0234572021.USD","SG9999002232.USD","LU1066051811.HKD","LU1934455277.USD","NVOH","SG9999001176.SGD","BK4559","IE00BBT3K403.USD","LU1941712264.USD","IE00BLSP4452.SGD","BK4532","IE00B1BXHZ80.USD","LU2023250843.SGD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU1037948897.HKD","LU0106261372.USD","LU0203345920.USD","SG9999002224.SGD","LU0289739699.SGD","LU2112291526.USD","NVOX","LU1974910355.USD","LU2023250504.SGD","SG9999014575.USD","LU1057294990.SGD","BK4516","SG9999014542.SGD","LU0861579265.USD","LU0265550946.USD","LU1093756168.USD","IE00BSNM7G36.USD","IE000M9KFDE8.USD","LU0868494708.USD","LU0432979614.USD","BK4585","BK4504","LU0965509101.SGD","LU1061106388.HKD","BK4599","MRK","LU1934455194.USD","BK4533","CQQQ","LU2461242641.AUD","LU1929549753.HKD","LU0154236417.USD","LU2125154778.USD","ASHR","LU0965509010.AUD","DRAG","LU0006306889.USD","LU1066051225.USD","LU2125154935.USD","SG9999015358.SGD","SG9999014559.SGD","IE00B2B36J28.USD","LU2361044865.SGD","LU0942090050.USD","LU1430594728.SGD","NVO","LU0122379950.USD","TAK","LU1037948541.HKD","LU2361044949.HKD","LU1066051498.USD","LU0963586101.USD","LU0208291251.USD","LU1989771016.USD","SG9999013999.USD","LU1291159041.SGD","LU1035773651.USD","IE00BKVL7J92.USD","LU1983299246.USD","LU1093756325.SGD","LU2089984988.USD","BK4550","LU1069347547.HKD","LU2360032135.SGD","IE00BJT1NW94.SGD","SG9999015341.SGD","LU0965509283.SGD","LU1989772840.SGD","LU0130102774.USD","BK4614","LU1023059063.AUD","IE0009355771.USD","LU1989772923.USD","SG9999001440.SGD","ASHS","BK4534","MCHI","LU1201861249.SGD","LU0320765646.SGD","IE00BFTCPJ56.SGD","BK4007","LU1585245621.USD","LU2106854487.HKD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU1934455863.HKD","LU0266013472.USD","CWEB","IE0002141913.USD","LU0980610538.SGD","IE00B4R5TH58.HKD","LU0320765489.SGD","LU2324357040.USD"],"gpt_icon":0},{"id":"2616034538","title":"大摩下调诺和诺德目标价至40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616034538","media":"中金财经","labels":["rating"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616034538?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:57","pubTimestamp":1772614622,"startTime":"0","endTime":"0","summary":"摩根士丹利将诺和诺德的目标价从42美元下调至40美元，评级则从“减持”上调“持股观望”。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260304/32044400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4007","BK4585","IE00BKVL7J92.USD","LU1093756325.SGD","BK4532","BK4599","LU1093756168.USD","NVO","NVOH","IE00BZ1G4Q59.USD","BK4588","LU0154236417.USD","NVOX"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0202},{"period":"1month","weight":-0.4365},{"period":"3month","weight":-0.4538},{"period":"6month","weight":-0.7002},{"period":"1year","weight":-0.8585},{"period":"ytd","weight":-0.5135}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"2倍做多NVO ETF-Defiance","nameEN":"Defiance Daily Target 2X Long NVO ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"2倍做多NVO ETF-Defiance,NVOX,2倍做多NVO ETF-Defiance股票,2倍做多NVO ETF-Defiance股票老虎,2倍做多NVO ETF-Defiance股票老虎国际,2倍做多NVO ETF-Defiance行情,2倍做多NVO ETF-Defiance股票行情,2倍做多NVO ETF-Defiance股价,2倍做多NVO ETF-Defiance股市,2倍做多NVO ETF-Defiance股票价格,2倍做多NVO ETF-Defiance股票交易,2倍做多NVO ETF-Defiance股票购买,2倍做多NVO ETF-Defiance股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}